Proteome Sciences Statement re Share Price Movement

Statement re Share Price Movement

5th February 2008

The Board of Proteome Sciences has noted the recent movement in the Company’s share price and that they are not aware of any reason for the share price increase.

In the trading update released on 21 December 2007, the Board reported that it continued to view future prospects for TMT® commercialisation with increasing confidence, with the related licence negotiations expected to be concluded in early 2008. This remains the case and the Company will issue a further update on licence negotiations in due course.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.